FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 12-2004)

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/533081

INTERNATIONAL APPLICATION NO. PCT/JP03/13848

INTERNATIONAL FILING DATE 29 October 2003

PRIORITY DATE CLAIMED 29 October 2002

271529US0PCT

	_	101/103/13040							
QUIN	OLI	NVENTION NE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF FLT3 AND AL COMPOSITIONS CONTAINING THE SAME							
APPL	ICAN ⁻	T(S) FOR DO/EO/US							
Hisan	naru 1	HIRAI et al.							
Applic	ant he	erewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:							
1.	\boxtimes	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.							
2.		7,110							
3.	\boxtimes	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6) (9) and (24) indicated below.							
4.	\boxtimes	The US has been elected (Article 31).							
5.	A copy of the International Application as filed (35 U.S.C. 371 (c)(2))								
		a. is attached hereto (required only if not communicated by the International Bureau).							
		b. 🛮 has been communicated by the International Bureau.							
		c. is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
		a. is attached hereto.							
		b. has been previously submitted under 35 U.S.C. 154(d)(4).							
7.	\boxtimes	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))							
		a. are attached hereto (required only if not communicated by the International Bureau).							
		b. have been communicated by the International Bureau.							
		c. have not been made; however, the time limit for making such amendments has NOT expired.							
		d. 🛛 have not been made and will not be made.							
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).							
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).							
11.	\boxtimes	A copy of the International Preliminary Examination Report (PCT/IPEA/409).							
12.	\boxtimes	A copy of the International Search Report (PCT/ISA/210).							
It	ems 1	13 to 23 below concern document(s) or information included:							
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
15.		A FIRST preliminary amendment.							
16.		A SECOND or SUBSEQUENT preliminary amendment.							
17.		A substitute specification.							
18.		A power of attorney and/or change of address letter.							
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.							
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
21.		A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).							
22.		Express Mail Label No.							
23.	\boxtimes	Other items or information:							
		Application Data Sheet Notice of Priority							
		PCT/IB/304 PCT/IB/308 Request for Consideration of Documents Cited in International Search Report							
1		•							

JC12 Rec'd PCT/PTC 2 8 A PR 2005

PTO-1390 (Rev. 12-2004)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.						ATTORNEY'S DOCKET NUMBER				
1	0/533	271529US0PCT								
	g fees are submitte	Applicant use	Office use							
•	ional fee	\$ \$300.00	<u> </u>							
· ·	tion fee	\$ \$200.00								
⊠ c) Search fe	e	\$ \$400.00								
	AL OF ABOVE	\$ \$900.00								
Additional fe sequence lis \$250 for each	e for specification ting or computer p h additional 50 sh		•							
Total Sheets	heets Extra Sheets Number of each additional 50 or fraction thereof (round up to a whole									
- 100 =	- 100 = /50 =				× \$250.00	\$ \$0.00				
	0.00 for furnishing priority date (37 Cl	\$ \$130.00								
CLAIMS	NUMBER F	MBER FILED NUMBER EXTRA			RATE					
Total claims		- 20 =	0	×	\$50.00	\$ \$0.00				
Independent clair	ns	- 3=	0	х	\$200.00	\$ \$0.00				
MULTIPLE DEPE	NDENT CLAIMS	(if applicable) 🗆	+	\$360.00	\$ \$0.00				
	\$ \$1,030.00									
Applicant cla reduced by 1	ims small entity st /2.	\$ \$0.00								
					UBTOTAL =	\$ \$1,030.00				
Processing fee of the earliest claims	\$130.00 for furnised priority date (3)	hing the Eng 7 CFR 1.492	llish translation later th	an 30) months from	\$ \$130.00				
			TOTAL N	IATI	ONAL FEE =	\$ \$1,160.00				
Fee for recording accompanied by a	the enclosed assign appropriate cov	gnment (37 (er sheet (37	CFR 1.21(h)). The ass CFR 3.28, 3.31). \$40	ignm per p	ent must be property +	\$ \$0.00				
		\$ \$1,160.00								
			\$							
			\$							
a. A check in the amount of \$ to cover the above fees is enclosed.										
b. Please c A duplica										
c. The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No15-0030 A duplicate copy of this sheet is enclosed.										
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card Information should not be included on this form. Provide credit card information and authorization on PTO-2038.										
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.										
	ESPONDENCE T			.o po	y status.	land land				
Customer Number SIGNA						uwan joer	<u> </u>			
22850 Surinder Sachar										
Registration No. 34,423 NAME										
		ION NUMBER								

DOCKET NO.: 271529US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hisamaru HIRAI, et al.

SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HEREWITH

INTERNATIONAL APPLICATION NO.: PCT/JP03/13848

INTERNATIONAL FILING DATE: October 29, 2003

FOR: QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF FLT3 AND MEDICINAL COMPOSITIONS CONTAINING

THE SAME

REQUEST FOR CONSIDERATION OF DOCUMENTS CITED IN INTERNATIONAL SEARCH REPORT

Commissioner for Patents Alexandria, Virginia 22313

Sir:

In the matter of the above-identified application for patent, notice is hereby given that applicant(s) request that the Examiner consider the documents cited in the International Search Report according to MPEP §609 and so indicate by a statement in the first Office Action that the information has been considered. When the Form PCT/DO/EO/903 indicates both the search report and copies of the documents are present in the national stage file, there is no requirement for the applicant(s) to submit them (1156 O.G. 91 November 23, 1993).

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon Attorney of Record Registration No. 24,618 Surinder Sachar

Registration No. 34,423

Customer Number 22850

(703) 413-3000 Fax No. (703) 413-2220 (OSMMN 08/03)